34 related articles for article (PubMed ID: 18634847)
1. Anti-cancer effects of celecoxib in head and neck carcinoma.
Kim YY; Lee EJ; Kim YK; Kim SM; Park JY; Myoung H; Kim MJ
Mol Cells; 2010 Feb; 29(2):185-94. PubMed ID: 20082220
[TBL] [Abstract][Full Text] [Related]
2. Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and on
Uram Ł; Pieńkowska N; Misiorek M; Szymaszek Ż; Twardowska M; Siorek M; Wołowiec S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542198
[TBL] [Abstract][Full Text] [Related]
3. Autophagy Determines the Path on the TRAIL to Death.
Sakamaki JI; Ryan KM
Dev Cell; 2016 May; 37(4):291-293. PubMed ID: 27219055
[TBL] [Abstract][Full Text] [Related]
4. Hydrogen Ion Dynamics of Cancer and a New Molecular, Biochemical and Metabolic Approach to the Etiopathogenesis and Treatment of Brain Malignancies.
Harguindey S; Polo Orozco J; Alfarouk KO; Devesa J
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31480530
[TBL] [Abstract][Full Text] [Related]
5. Use of statins or NSAIDs and survival of patients with high-grade glioma.
Seliger C; Schaertl J; Gerken M; Luber C; Proescholdt M; Riemenschneider MJ; Leitzmann MF; Hau P; Klinkhammer-Schalke M
PLoS One; 2018; 13(12):e0207858. PubMed ID: 30507932
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib in breast cancer prevention and therapy.
Li J; Hao Q; Cao W; Vadgama JV; Wu Y
Cancer Manag Res; 2018; 10():4653-4667. PubMed ID: 30464589
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer activity of ZnO chips by sustained zinc ion release.
Moon SH; Choi WJ; Choi SW; Kim EH; Kim J; Lee JO; Kim SH
Toxicol Rep; 2016; 3():430-438. PubMed ID: 28959565
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.
Wood K; Byron E; Janisch L; Salgia R; Sharma MR
Am J Clin Oncol; 2018 Oct; 41(10):963-966. PubMed ID: 28654574
[TBL] [Abstract][Full Text] [Related]
9. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.
von Karstedt S; Montinaro A; Walczak H
Nat Rev Cancer; 2017 May; 17(6):352-366. PubMed ID: 28536452
[TBL] [Abstract][Full Text] [Related]
10. Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma.
Seliger C; Meier CR; Becker C; Jick SS; Bogdahn U; Hau P; Leitzmann MF
PLoS One; 2016; 11(2):e0149293. PubMed ID: 26871579
[TBL] [Abstract][Full Text] [Related]
11. The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma.
van Roosmalen IAM; Reis CR; Setroikromo R; Yuvaraj S; Joseph JV; Tepper PG; Kruyt FAE; Quax WJ
Springerplus; 2014; 3(1):495. PubMed ID: 26331107
[TBL] [Abstract][Full Text] [Related]
12. Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model.
Perumal V; Banerjee S; Das S; Sen RK; Mandal M
Cancer Nanotechnol; 2011; 2(1-6):67-79. PubMed ID: 26069486
[TBL] [Abstract][Full Text] [Related]
13. Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.
Mercurio S; Padovani L; Colin C; Carré M; Tchoghandjian A; Scavarda D; Lambert S; Baeza-Kallee N; Fernandez C; Chappé C; André N; Figarella-Branger D
Acta Neuropathol Commun; 2013 May; 1():17. PubMed ID: 24252689
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells.
Carminati PO; Donaires FS; Marques MM; Donadi EA; Passos GA; Sakamoto-Hojo ET
Mol Biol Rep; 2014 Jan; 41(1):165-77. PubMed ID: 24218165
[TBL] [Abstract][Full Text] [Related]
15. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
16. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.
Sareddy GR; Geeviman K; Ramulu C; Babu PP
J Neurooncol; 2012 Jan; 106(1):99-109. PubMed ID: 21847707
[TBL] [Abstract][Full Text] [Related]
17. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Gilbert MR; Gonzalez J; Hunter K; Hess K; Giglio P; Chang E; Puduvalli V; Groves MD; Colman H; Conrad C; Levin V; Woo S; Mahajan A; de Groot J; Yung WK
Neuro Oncol; 2010 Nov; 12(11):1167-72. PubMed ID: 20729242
[TBL] [Abstract][Full Text] [Related]
18. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
19. TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin.
Gaiser T; Becker MR; Habel A; Reuss DE; Ehemann V; Rami A; Siegelin MD
Neurosci Lett; 2008 Sep; 442(2):109-13. PubMed ID: 18634847
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
